Triple Combination Therapy for Resistant Hypertension
Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)
Recruiting
N/A
Interventional Study
Apparent Resistant Hypertension
Hypertension
High Blood Pressure
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 142 (estimated)
- Sponsor
- Instituto Dante Pazzanese de Cardiologia · Other
Who this trial is looking for
This trial is looking for adults aged 18 to 75 with high blood pressure that is hard to treat. Participants will compare a new simpler medication strategy to usual care over 12 weeks.
Are You a Good Fit for This Trial?
You may be able to join if
- I am between 18 and 75 years old.
- I have high blood pressure that is difficult to control.
- I have been treated with 3 to 5 different blood pressure medications.
- My recent blood pressure monitoring showed values above target.
- My office blood pressure is at least 140/90 mmHg.
- I have poor adherence to my current treatment.
You may not be able to join if
- I have secondary hypertension.
- I have had serious side effects from blood pressure medications.
- I need to take beta-blockers or mineralocorticoid receptor antagonists.
- My office blood pressure is 220/120 mmHg or higher.
- I have a reduced left ventricular ejection fraction.
- I have severe kidney problems.
- I have atrial fibrillation or atrial flutter.
- I am pregnant or breastfeeding.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a single-center, open-label, randomized clinical trial conducted at the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. The study evaluates a simplified treatment strategy for patients with apparent resistant hypertension, comparing fixed triple combination therapy (perindopril, indapamide, and amlodipine) with usual care using multiple separate antihypertensive drugs. The pri…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria: Age between 18 and 75 years;
Treatment with 3 to 5 classes of antihypertensive drugs, including a maximum dose of an ACE inhibitor or ARB, a thiazide or thiazide-like diuretic, and a calcium channel blocker (CCB);
Recent 24-hour ambulatory blood pressure monitoring (ABPM) (\<1 …
Contacts